<inf:proxyVoteTable xmlns:inf="http://www.sec.gov/edgar/document/npxproxy/informationtable">
  <inf:proxyTable>
    <inf:issuerName>IMMUNIC INC</inf:issuerName>
    <inf:cusip>4525EP101</inf:cusip>
    <inf:meetingDate>6/11/2024</inf:meetingDate>
    <inf:voteDescription>To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:voteSource>ISSUER</inf:voteSource>
    <inf:sharesVoted>1788160</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>AGAINST</inf:howVoted>
        <inf:sharesVoted>1788160</inf:sharesVoted>
        <inf:managementRecommendation>AGAINST</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>KRONOS BIO INC</inf:issuerName>
    <inf:cusip>50107A104</inf:cusip>
    <inf:meetingDate>6/25/2024</inf:meetingDate>
    <inf:voteDescription>To approve, on an advisory basis, the compensation of the Company?s Named Executive Officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:voteSource>ISSUER</inf:voteSource>
    <inf:sharesVoted>326548</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>FOR</inf:howVoted>
        <inf:sharesVoted>326548</inf:sharesVoted>
        <inf:managementRecommendation>FOR</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>MORPHIC HLDG INC</inf:issuerName>
    <inf:cusip>61775R105</inf:cusip>
    <inf:meetingDate>6/4/2024</inf:meetingDate>
    <inf:voteDescription>To approve, on a non-binding advisory basis, the compensation paid to the Company?s Named Executive Officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:voteSource>ISSUER</inf:voteSource>
    <inf:sharesVoted>159846</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>ABSTAIN</inf:howVoted>
        <inf:sharesVoted>159846</inf:sharesVoted>
        <inf:managementRecommendation>NONE</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
  <inf:proxyTable>
    <inf:issuerName>SYROS PHARMACEUTICALS INC</inf:issuerName>
    <inf:cusip>87184Q206</inf:cusip>
    <inf:meetingDate>6/5/2024</inf:meetingDate>
    <inf:voteDescription>The approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.</inf:voteDescription>
    <inf:voteCategories>
      <inf:voteCategory>
        <inf:categoryType>SECTION 14A SAY-ON-PAY VOTES</inf:categoryType>
      </inf:voteCategory>
    </inf:voteCategories>
    <inf:voteSource>ISSUER</inf:voteSource>
    <inf:sharesVoted>251270</inf:sharesVoted>
    <inf:sharesOnLoan>0</inf:sharesOnLoan>
    <inf:vote>
      <inf:voteRecord>
        <inf:howVoted>ABSTAIN</inf:howVoted>
        <inf:sharesVoted>251270</inf:sharesVoted>
        <inf:managementRecommendation>NONE</inf:managementRecommendation>
      </inf:voteRecord>
    </inf:vote>
  </inf:proxyTable>
</inf:proxyVoteTable>
